Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer.

Eiber, Matthias; Rauscher, Isabel; Souvatzoglou, Michael; Maurer, Tobias; Schwaiger, Markus; Holzapfel, Konstantin; Beer, Ambros J

doi:10.1007/s00259-017-3797-y

User: Guest

2017

Back
Back to start of result list
Permanent link for displayed object

Document type:: Journal Article; Article
Author(s):: Eiber, Matthias; Rauscher, Isabel; Souvatzoglou, Michael; Maurer, Tobias; Schwaiger, Markus; Holzapfel, Konstantin; Beer, Ambros J
Title:: Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer.
Abstract:: Whole-body integrated 11C-choline PET/MR might provide advantages compared to 11C-choline PET/CT for restaging of prostate cancer (PC) due to the high soft-tissue contrast and the use of multiparametric MRI, especially for detection of local recurrence and bone metastases.Ninety-four patients with recurrent PC underwent a single-injection/dual-imaging protocol with contrast-enhanced PET/CT followed by fully diagnostic PET/MR. Imaging datasets were read separately by two reader teams (team 1 and 2) assessing the presence of local recurrence, lymph node and bone metastases in predefined regions using a five-point scale. Detection rates were calculated. The diagnostic performance of PET/CT vs. PET/MR was compared using ROC analysis. Inter-observer and inter-modality variability, radiation exposure, and mean imaging time were evaluated. Clinical follow-up, imaging, and/or histopathology served as standard of reference (SOR).Seventy-five patients qualified for the final image analysis. A total of 188 regions were regarded as positive: local recurrence in 37 patients, 87 regions with lymph node metastases, and 64 regions with bone metastases. Mean detection rate between both readers teams for PET/MR was 84.7% compared to 77.3% for PET/CT (p > 0.05). Local recurrence was identified significantly more often in PET/MR compared to PET/CT by team 1. Lymph node and bone metastases were identified significantly more often in PET/CT compared to PET/MR by both teams. However, this difference was not present in the subgroup of patients with PSA values <=2 ng/ml. Inter-modality and inter-observer agreement (K > 0.6) was moderate to substantial for nearly all categories. Mean reduction of radiation exposure for PET/MR compared to PET/CT was 79.7% (range, 72.6-86.2%). Mean imaging time for PET/CT was substantially lower (18.4 ± 0.7 min) compared to PET/MR (50.4 ± 7.9 min).11C-choline PET/MR is a robust imaging modality for restaging biochemical recurrent PC and interpretations between different readers are consistent. It provides a higher diagnostic value for detecting local recurrence compared to PET/CT with the advantage of substantial dose reduction. Drawbacks of PET/MR are a substantially longer imaging time and a slight inferiority in detecting bone and lymph node metastases in patients with PSA values >2 ng/ml. Thus, we suggest the use of 11C-choline PET/MR especially for patients with low (<=2 ng/ml) PSA values, whereas PET/CT is preferable in the subgroup with higher PSA values.
Journal title abbreviation:: Eur J Nucl Med Mol Imaging
Year:: 2017
Journal volume:: 44
Journal issue:: 13
Pages contribution:: 2179-2188
Language:: eng
Fulltext / DOI:: doi:10.1007/s00259-017-3797-y
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/28803358
Print-ISSN:: 1619-7070
TUM Institution:: Klinik und Poliklinik für Nuklearmedizin; Urologische Klinik und Poliklinik
BibTeX